{"doc_id": "33212256", "type of study": "Therapy", "title": "", "abstract": "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.\nTo assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19).\nIn this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18-75 years) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms (including asymptomatic) were randomized 1:1 to oral favipiravir (day 1: 1800 mg BID and days 2-14: 800 mg BID) plus standard supportive care versus supportive care alone.\nThe primary endpoint was time to the cessation of viral shedding; time to clinical cure was also measured.\nFrom May 14 to July 3, 2020, 150 patients were randomized to favipiravir (n = 75) or control (n = 75).\nMedian time to the cessation of viral shedding was 5 days (95% CI: 4 days, 7 days) versus 7 days (95% CI: 5 days, 8 days), P = 0.129, and median time to clinical cure was 3 days (95% CI: 3 days, 4 days) versus 5 days (95% CI: 4 days, 6 days), P = 0.030, for favipiravir and control, respectively.\nAdverse events were observed in 36% of favipiravir and 8% of control patients.\nOne control patient died due to worsening disease.\nThe lack of statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay.\nSignificant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19.\nCopyright \u00a9 2020 The Author(s).\nPublished by Elsevier Ltd.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "mild-to-moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 114}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 58}, {"term": "mild-to-moderate coronavirus disease 2019 (", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 107}, {"term": "RT-PCR confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 130}, {"term": "mild-to-moderate symptoms", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 160}, {"term": "asymptomatic", "negation": "affirmed", "UMLS": {}, "start": 173, "end": 185}, {"term": "mild-to-moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 116}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Efficacy and safety of favipiravir , an oral RNA-dependent RNA polymerase inhibitor , in mild-to-moderate COVID-19 : A randomized , comparative, open-label, multicenter, phase 3 clinical trial .", "Evidence Elements": {"Participant": [{"term": "mild-to-moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 114}], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 34, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "Efficacy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 8}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 58}, {"term": "mild-to-moderate coronavirus disease 2019 (", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 107}], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 48, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 22}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 33}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this randomized , open-label, parallel-arm, multicenter , phase 3 trial , adults ( 18-75 years ) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms ( including asymptomatic ) were randomized 1:1 to oral favipiravir ( day 1: 1800 mg BID and days 2-14 : 800 mg BID ) plus standard supportive care versus supportive care alone .", "Evidence Elements": {"Participant": [{"term": "RT-PCR confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 130}, {"term": "mild-to-moderate symptoms", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 160}, {"term": "asymptomatic", "negation": "affirmed", "UMLS": {}, "start": 173, "end": 185}], "Intervention": [{"term": "oral favipiravir", "negation": "affirmed", "UMLS": {}, "start": 211, "end": 227, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 5, "end": 16, "has_route": ["oral"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary endpoint was time to the cessation of viral shedding ; time to clinical cure was also measured .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "time to the cessation of viral shedding", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 64}, {"term": "time to clinical cure", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 88}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "From May 14 to July 3 , 2020 , 150 patients were randomized to favipiravir ( n = 75 ) or control ( n = 75 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 74, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Median time to the cessation of viral shedding was 5 days ( 95 % CI : 4 days , 7 days ) versus 7 days ( 95 % CI : 5 days , 8 days ) , P=0.129 , and median time to clinical cure was 3 days ( 95 % CI : 3 days , 4 days ) versus 5 days ( 95 % CI : 4 days , 6 days ) , P=0.030 , for favipiravir and control , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Median time to the cessation of viral shedding", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 46}, {"term": "median time to clinical cure", "negation": "affirmed", "UMLS": {}, "start": 148, "end": 176}], "Observation": [{"term": "5 days", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 57}, {"term": "7 days", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 85}, {"term": "3 days", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 187}, {"term": "5", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 52}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Adverse events were observed in 36 % of favipiravir and 8 % of control patients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 51, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}], "Observation": [], "Count": [{"term": "36 %", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 36}, {"term": "8 %", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 59}]}, "Evidence Propositions": [{"Intervention": {"term": "favipiravir", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "", "Count": "36 %", "Outcome": "Adverse events"}]}, {"Section": "RESULTS", "Text": "One control patient died due to worsening disease .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "control patient", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 19}, {"term": "died", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 24}, {"term": "worsening disease", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 49}], "Observation": [], "Count": [{"term": "One", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}]}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "The lack of statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [{"term": "lack of statistical significance", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 36}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Significant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19 .", "Evidence Elements": {"Participant": [{"term": "mild-to-moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 116}], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 69, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "time to clinical cure", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 48}], "Observation": [{"term": "Significant improvement", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23}, {"term": "beneficial", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 87}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "favipiravir", "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "Significant improvement", "Outcome": "time to clinical cure", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 The Author (s ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier Ltd . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}